“GLP-3” Explained
"GLP-3" is an informal nickname, not a scientific term. There is no GLP-3 hormone and no GLP-3 receptor. The name circulates because retatrutide acts on three receptors, and "three" was read into the numbering.
Key concepts
- There is no GLP-3 hormone or receptor
- GLP-1 and GLP-2 numbering refers to proglucagon products, not receptor counts
- "GLP-3" is informal shorthand for a triple receptor agonist
- Correct terminology is required to find the primary literature
- Precise naming keeps research records searchable and unambiguous
No such hormone or receptor exists
GLP-1 and GLP-2 are real, distinct proglucagon-derived peptides with their own receptors. The numbering refers to those cleavage products, not to how many receptors a drug targets. There is no third member called GLP-3 and no GLP-3 receptor in the receptor nomenclature.
So a search for GLP-3 will not find a hormone. It finds informal discussion of triple receptor agonists, retatrutide most often among them.
| Term | Status | Notes |
|---|---|---|
| GLP-1 | Real hormone and receptor | Incretin from intestinal L-cells |
| GLP-2 | Real hormone and receptor | Intestinal growth and barrier research |
| "GLP-3" | Informal nickname only | No hormone, no receptor, no official use |
| Triple receptor agonist | Correct description | GIP + GLP-1 + glucagon receptor activity |
Why the nickname stuck
The field moved from single to dual to triple receptor agonists in quick succession, and shorthand followed the pattern rather than the science. "GLP-3" reads as the next step in a sequence, which makes it memorable and wrong at the same time.
The nickname is used in general discussion rather than in published pharmacology. Developer and regulatory documents describe retatrutide as a GIP, GLP-1 and glucagon receptor agonist.
The terminology to use instead
For any research record, describe retatrutide as a triple receptor agonist, or spell out the three receptors. Reserve "GLP-3" for explaining why other people use it, which is what this page does.
Precision here has a practical payoff: correct terminology returns the actual characterisation literature when searching PubMed or clinical trial registries, whereas the nickname does not.
Related naming confusions worth flagging
The informal habit of numbering by receptor count also produces occasional references to a molecule as a "quadruple" or higher-order agonist once a fourth mechanism, such as amylin receptor activity, is added in some other investigational compound. The same caution applies: receptor count is not standard nomenclature, and the accurate description is always to name the receptors engaged.
Search engines and forums propagate these nicknames faster than they propagate corrections, so a term appearing frequently in casual discussion is not evidence that it is scientifically accurate. Checking a term against a primary characterisation paper or a regulatory pipeline description is a reliable way to separate informal shorthand from established nomenclature.
Why precise terminology matters for research records
A laboratory notebook, protocol or internal report that uses "GLP-3" risks being unsearchable against the primary literature and unclear to any reader unfamiliar with the informal usage. Recording the compound as a triple receptor agonist with the three receptors named removes that ambiguity entirely.
The same applies to any published or shared material describing retatrutide: research use only labelling and accurate receptor terminology together reduce the risk that informal shorthand is mistaken for an approved drug name or a distinct hormone class.
Assay and model-system implications of using correct terminology
Beyond the naming question itself, using the correct triple receptor agonist description has a practical consequence for experimental design: it signals directly that three separate receptor-level assays, or a system expressing all three receptors, are relevant to characterising the compound, whereas a GLP-1-focused label could lead a researcher unfamiliar with the compound to assume a single-receptor assay is sufficient.
This is not a purely semantic point. A study designed around the assumption that retatrutide behaves like a GLP-1-class compound could miss glucagon receptor-mediated effects entirely, simply because the model system chosen, such as a pure GLP-1 receptor-expressing cell line, has no capacity to report on that arm of the pharmacology.
Verifying identity of supplied material regardless of nickname
Whatever informal name a compound is discussed under, the material used in a laboratory should be verified against its formal identity: mass spectrometry for molecular mass, HPLC for purity, and cross-reference to the batch certificate of analysis. Informal nicknames carry no analytical information and should never be treated as a substitute for checking that supplied material matches the intended peptide.
This is a general principle across the peptide research supply chain, not one specific to retatrutide, but it is worth restating here because informal terminology like a nickname can create a false impression of familiarity with a compound that has not actually been analytically confirmed in the researcher’s own hands.
Where the terminology question is settled and where it is not
That no GLP-3 hormone or receptor exists, and that retatrutide is correctly described as a triple receptor agonist, are both settled points that can be checked directly against receptor nomenclature databases and the primary characterisation paper. What remains a live question is how the individual receptor potencies reported for retatrutide compare, in matched assay conditions, with other multi-receptor agonists under development, since public comparative data across compounds in this space is limited.
Researchers wanting to track how the field’s vocabulary develops as more multi-receptor peptides enter development should expect further informal nicknames to arise by analogy, and should apply the same check each time: confirm the actual receptors named in the primary source rather than inferring them from a numbering pattern in casual usage.
Strength of the current evidence
That no GLP-3 receptor exists is settled nomenclature. Use of the nickname is a matter of popular usage only.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Incretin receptor pharmacology literature (GIP, GLP-1, glucagon receptors) (PubMed search listing)
Related Retatrutide research
- Is Retatrutide a GLP-1? — Why retatrutide is more accurately described as a triple receptor agonist than as a GLP-1 agonist, and what the distinction changes.
- Retatrutide Receptors — The three receptors retatrutide is designed to activate, what each one does, and why the balance between them defines the molecule.
- Triple Receptor Agonism — What triple receptor agonism means in peptide design, and how balance between receptors is characterised.
- Retatrutide Peptide Profile — Reference profile for retatrutide as a peptide: designation, class, receptor targets, format and batch testing.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.